Details

Autor(en) / Beteiligte

• Kumar, Sanjeev
• Chandele, Anmol
• Sharma, Amit
• Evans, Matthew J.

Titel

Current status of therapeutic monoclonal antibodies against SARS-CoV-2

Ist Teil von

• PLoS pathogens, 2021-09, Vol.17 (9), p.e1009885-e1009885

Ort / Verlag

San Francisco: Public Library of Science

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Electronic Journals Library - Freely accessible e-journals

Beschreibungen/Notizen

• To this end, very recently, a formulation of human mAbs (casirivimab and imdevimab) against SARS-CoV-2 was approved for passive immunotherapy in mild and moderately severe COVID-19 cases in India and elsewhere. [...]it is valuable and timely to summarize the specificity and reactivity of human mAbs against SARS-CoV-2 and its rapidly emerging variants. Primary targets of SARS-CoV-2 therapeutic neutralizing antibodies The spike (S) protein of SARS-CoV-2 is the primary target of neutralizing antibodies (NAbs) (Fig 1A). [...]NAbs against SARS-CoV-2 that have either been deployed for therapy or are in advanced stage trials, for the most part, either target the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the spike glycoprotein (Fig 1A and 1B) [1,2]. CP, cytoplasmic tail; FP, fusion peptide; HR1, heptad repeat 1; HR2, heptad repeat 2; mAb, monoclonal antibody; NTD, N-terminal domain; PDB, Protein Data Bank; RBD, receptor-binding domain; RBM, receptor-binding motif; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; SP, signal peptide; TM, transmembrane domain. https://doi.org/10.1371/journal.ppat.1009885.g001 Therapeutic COVID-19 mAbs in the clinic and in clinical trials Therapeutic mAbs for COVID-19 treatment have been developed in accelerated time and the pace has been unprecedented for any disease. According to the World Health Organization (WHO), a recognized mutation is elevated to a “variant of concern” (VOC) when the acquisition of a new mutation allows for increased viral transmission, increased fatality, and a significant decrease in the effectiveness of therapy and vaccines.